0
     

Report Added
Report already added
Alzheimer's Disease Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Alzheimer's Disease Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Alzheimer's Disease - Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update, provides an overview of the Alzheimer's Disease (Central Nervous System) pipeline landscape.

Alzheimer's disease is a progressive, degenerative condition causing damage to the memory and behavior due to the attack on the neurons. These neurons are responsible for the synthesis of neurotransmitter acetylcholine which is further responsible for the transmission of signals. Predisposing factors include age, heredity, cardiovascular diseases or diabetes and environmental factors. Symptoms include depression, anxiety, social withdrawal, irritability and aggressiveness.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Alzheimer's Disease - Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update, provides comprehensive information on the therapeutics under development for Alzheimer's Disease (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Alzheimer's Disease (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Alzheimer's Disease and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Phase 0, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 1, 24, 76, 100, 1, 9, 387, 203 and 8 respectively. Similarly, the Universities portfolio in Phase III, Phase II, Phase I, Preclinical and Discovery stages comprises 1, 3, 2, 109 and 52 molecules, respectively.

Alzheimer's Disease (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Alzheimer's Disease (Central Nervous System).
- The pipeline guide reviews pipeline therapeutics for Alzheimer's Disease (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Alzheimer's Disease (Central Nervous System) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Alzheimer's Disease (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Alzheimer's Disease (Central Nervous System)

Reasons to Buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Alzheimer's Disease (Central Nervous System).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Alzheimer's Disease (Central Nervous System) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Alzheimer's Disease - Overview
Alzheimer's Disease - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Alzheimer's Disease - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Alzheimer's Disease - Companies Involved in Therapeutics Development
Alzheimer's Disease - Drug Profiles
Alzheimer's Disease - Dormant Projects
Alzheimer's Disease - Discontinued Products
Alzheimer's Disease - Product Development Milestones
Featured News & Press Releases
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products under Development for Alzheimer's Disease, 2022
Number of Products under Development by Companies, 2022
Number of Products under Development by Universities/Institutes, 2022
Products under Development by Companies, 2022
Products under Development by Universities/Institutes, 2022
Number of Products by Stage and Target, 2022
Number of Products by Stage and Mechanism of Action, 2022
Number of Products by Stage and Route of Administration, 2022
Number of Products by Stage and Molecule Type, 2022
Alzheimer's Disease - Pipeline by 1st Bio Therapeutics Inc, 2022
Alzheimer's Disease - Pipeline by 2A Pharma AB, 2022
Alzheimer's Disease - Pipeline by 4B Technologies (Suzhou) Co Ltd, 2022
Alzheimer's Disease - Pipeline by 4P-Pharma SAS, 2022
Alzheimer's Disease - Pipeline by AB Science SA, 2022
Alzheimer's Disease - Pipeline by Abaxy Sprl, 2022
Alzheimer's Disease - Pipeline by AbbVie Inc, 2022
Alzheimer's Disease - Pipeline by Abrexa Pharmaceuticals Inc, 2022
Alzheimer's Disease - Pipeline by Abyssinia Biologics LLC, 2022
Alzheimer's Disease - Pipeline by AC Immune SA, 2022
Alzheimer's Disease - Pipeline by Acadia Pharmaceuticals Inc, 2022
Alzheimer's Disease - Pipeline by Accuitis Pharmaceuticals Inc, 2022
Alzheimer's Disease - Pipeline by Acelot Inc, 2022
Alzheimer's Disease - Pipeline by Actinogen Medical Ltd, 2022
Alzheimer's Disease - Pipeline by Acumen Pharmaceuticals Inc, 2022
Alzheimer's Disease - Pipeline by Addex Therapeutics Ltd, 2022
Alzheimer's Disease - Pipeline by ADEL Inc, 2022
Alzheimer's Disease - Pipeline by Adocia SAS, 2022
Alzheimer's Disease - Pipeline by ADRx Inc, 2022
Alzheimer's Disease - Pipeline by Aerobyx LLC, 2022
Alzheimer's Disease - Pipeline by Aeton Therapeutics Inc, 2022
Alzheimer's Disease - Pipeline by AevisBio Inc, 2022
Alzheimer's Disease - Pipeline by AfaSci Inc, 2022
Alzheimer's Disease - Pipeline by AIBIOS Co Ltd, 2022
Alzheimer's Disease - Pipeline by Ailon Co Ltd, 2022
Alzheimer's Disease - Pipeline by Akome Biotech Ltd, 2022
Alzheimer's Disease - Pipeline by Alchemab Therapeutics Ltd, 2022
Alzheimer's Disease - Pipeline by Alector Inc, 2022
Alzheimer's Disease - Pipeline by Alfasigma SpA, 2022
Alzheimer's Disease - Pipeline by Alkahest Inc, 2022
Alzheimer's Disease - Pipeline by Alkermes Plc, 2022
Alzheimer's Disease - Pipeline by Allyx Therapeutics Inc, 2022
Alzheimer's Disease - Pipeline by Alnylam Pharmaceuticals Inc, 2022
Alzheimer's Disease - Pipeline by Alopexx Inc, 2022
Alzheimer's Disease - Pipeline by AlphaCognition Inc, 2022
Alzheimer's Disease - Pipeline by Alsonex Pty Ltd, 2022
Alzheimer's Disease - Pipeline by ALSP Inc, 2022
Alzheimer's Disease - Pipeline by AltPep Corp, 2022
Alzheimer's Disease - Pipeline by Alzamend Neuro Inc, 2022
Alzheimer's Disease - Pipeline by AlzeCure Pharma AB, 2022
Alzheimer's Disease - Pipeline by Alzheon Inc, 2022
Alzheimer's Disease - Pipeline by Alzhyme Pty Ltd, 2022
Alzheimer's Disease - Pipeline by Alzinova AB, 2022
Alzheimer's Disease - Pipeline by AlzProtect SAS, 2022
Alzheimer's Disease - Pipeline by Amyloid Solution Inc, 2022
Alzheimer's Disease - Pipeline by Amylon LLC, 2022
Alzheimer's Disease - Pipeline by Amylyx Pharmaceuticals Inc, 2022
Alzheimer's Disease - Pipeline by AmyriAD Therapeutics BV, 2022
Alzheimer's Disease - Pipeline by Anavex Life Sciences Corp, 2022
Alzheimer's Disease - Pipeline by Anhorn Medicines Co Ltd, 2022
Alzheimer's Disease - Pipeline by Anima Biotech Inc, 2022
Alzheimer's Disease - Pipeline by Ankar Pharma SL, 2022
Alzheimer's Disease - Pipeline by ANLBio Co Ltd, 2022
Alzheimer's Disease - Pipeline by Annovis Bio Inc, 2022
Alzheimer's Disease - Pipeline by Antoxerene Inc, 2022
Alzheimer's Disease - Pipeline by Anven AlzDx Inc, 2022
Alzheimer's Disease - Pipeline by Aphios Corp, 2022
Alzheimer's Disease - Pipeline by Apollo Therapeutics LLC, 2022
Alzheimer's Disease - Pipeline by Applied Research using OMIC Sciences SL, 2022
Alzheimer's Disease - Pipeline by Aprinoia Therapeutics Inc, 2022
Alzheimer's Disease - Pipeline by AptaBio Therapeutics Inc, 2022
Alzheimer's Disease - Pipeline by Aquinnah Pharmaceuticals Inc, 2022
Alzheimer's Disease - Pipeline by Araclon Biotech SL, 2022
Alzheimer's Disease - Pipeline by Archer Pharmaceuticals Inc, 2022
Alzheimer's Disease - Pipeline by AriBio, 2022

List of Figures
Number of Products under Development for Alzheimer's Disease, 2022
Number of Products under Development by Companies, 2022
Number of Products under Development by Universities/Institutes, 2022
Number of Products by Top 10 Targets, 2022
Number of Products by Stage and Top 10 Targets, 2022
Number of Products by Top 10 Mechanism of Actions, 2022
Number of Products by Stage and Top 10 Mechanism of Actions, 2022
Number of Products by Top 10 Routes of Administration, 2022
Number of Products by Stage and Top 10 Routes of Administration, 2022
Number of Products by Top 10 Molecule Types, 2022
Number of Products by Stage and Top 10 Molecule Types, 2022

Report Title: Alzheimer's Disease Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update


Your Details
Valid Invalid number

SELECT A FORMAT

ADD TO CART BUY NOW

Related Report

China Bispecific Antibody Market Opportunity & Clinical Trials Insight 2028

China Bispecific Antibody Market Opportunity & Clinical Trials Insight 2028

2022 Vietnam Clinical Chemistry and Immunodiagnostic Analyzers and Reagents for 100 Abused Drug, Cancer, Chemistry, Endocrine, Immunoprotein, TDM and Other Tests -- High-Growth Opportunities for Suppliers, Competitive Shares and Growth Strategies, Volume and Sales Segment Forecasts through 2026, Latest Technologies and Instrumentation Pipeline

2022 Vietnam Clinical Chemistry and Immunodiagnostic Analyzers and Reagents for 100 Abused Drug, Cancer, Chemistry, Endocrine, Immunoprotein, TDM and Other Tests -- High-Growth Opportunities for Suppliers, Competitive Shares and Growth Strategies, Volume and Sales Segment Forecasts through 2026, Latest Technologies and Instrumentation Pipeline

2022 Venezuela Clinical Chemistry and Immunodiagnostic Analyzers and Reagents for 100 Abused Drug, Cancer, Chemistry, Endocrine, Immunoprotein, TDM and Other Tests -- High-Growth Opportunities for Suppliers, Competitive Shares and Growth Strategies, Volume and Sales Segment Forecasts through 2026, Latest Technologies and Instrumentation Pipeline

2022 Venezuela Clinical Chemistry and Immunodiagnostic Analyzers and Reagents for 100 Abused Drug, Cancer, Chemistry, Endocrine, Immunoprotein, TDM and Other Tests -- High-Growth Opportunities for Suppliers, Competitive Shares and Growth Strategies, Volume and Sales Segment Forecasts through 2026, Latest Technologies and Instrumentation Pipeline

2022 Uruguay Clinical Chemistry and Immunodiagnostic Analyzers and Reagents for 100 Abused Drug, Cancer, Chemistry, Endocrine, Immunoprotein, TDM and Other Tests -- High-Growth Opportunities for Suppliers, Competitive Shares and Growth Strategies, Volume and Sales Segment Forecasts through 2026, Latest Technologies and Instrumentation Pipeline

2022 Uruguay Clinical Chemistry and Immunodiagnostic Analyzers and Reagents for 100 Abused Drug, Cancer, Chemistry, Endocrine, Immunoprotein, TDM and Other Tests -- High-Growth Opportunities for Suppliers, Competitive Shares and Growth Strategies, Volume and Sales Segment Forecasts through 2026, Latest Technologies and Instrumentation Pipeline

2022 United Arab Emirates Clinical Chemistry and Immunodiagnostic Analyzers and Reagents for 100 Abused Drug, Cancer, Chemistry, Endocrine, Immunoprotein, TDM and Other Tests -- High-Growth Opportunities for Suppliers, Competitive Shares and Growth Strategies, Volume and Sales Segment Forecasts through 2026, Latest Technologies and Instrumentation Pipeline

2022 United Arab Emirates Clinical Chemistry and Immunodiagnostic Analyzers and Reagents for 100 Abused Drug, Cancer, Chemistry, Endocrine, Immunoprotein, TDM and Other Tests -- High-Growth Opportunities for Suppliers, Competitive Shares and Growth Strategies, Volume and Sales Segment Forecasts through 2026, Latest Technologies and Instrumentation Pipeline

2022 Ukraine Clinical Chemistry and Immunodiagnostic Analyzers and Reagents for 100 Abused Drug, Cancer, Chemistry, Endocrine, Immunoprotein, TDM and Other Tests -- High-Growth Opportunities for Suppliers, Competitive Shares and Growth Strategies, Volume and Sales Segment Forecasts through 2026, Latest Technologies and Instrumentation Pipeline

2022 Ukraine Clinical Chemistry and Immunodiagnostic Analyzers and Reagents for 100 Abused Drug, Cancer, Chemistry, Endocrine, Immunoprotein, TDM and Other Tests -- High-Growth Opportunities for Suppliers, Competitive Shares and Growth Strategies, Volume and Sales Segment Forecasts through 2026, Latest Technologies and Instrumentation Pipeline